You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


STORM Therapeutics’ METTL3 inhibitor moves closer to the clinic

University of Cambridge spin-out company STORM Therapeutics has announced that it has selected a first-in-class METTL3 candidate for development towards first in human clinical studies.